

<p>Substitute for form 1449A/PTO (Modified)</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				<b>Complete if Known</b>	
				Application Number	10/766,990
				Filing Date	January 28, 2004
				First Named Inventor	Gallop, Mark A.
				Art Unit	1626
				Examiner Name	Not Assigned
Sheet	1	of	4	Attorney Docket Number	34544/US/2/AMP/SKS (459258-00048)

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
<i>DW</i>	A1	3,845,770	11-05-1974	Theeuwes et al.	
	A2	3,916,899	11-04-1975	Theeuwes et al.	
	A3	4,765,539	08-23-1988	Noakes et al.	
	A4	4,962,885	10-16-1990	Coffee	
	A5	5,112,598	05-12-1992	Biesalski	
	A6	5,556,611	09-17-1996	Biesalski	
	A7	5,698,155	12-16-1997	Grosswald et al.	
	A8	5,950,619	09-14-1999	van der Linden et al.	
	A9	5,954,047	09-21-1999	Armer et al.	
	A10	5,970,974	10-26-1999	van der Linder et al.	
	A11 *	6,204,257 B1	03-20-2001	Stella et al.	
	A12 *	6,254,853 B1	07-03-2001	Hendler et al.	
	A13 *	6,362,234 B1	03-26-2002	Hendler	
<i>V</i>	A14	6,451,776 B2	09-17-2002	Stella et al.	

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No.	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
<i>DW</i>	B1	WO 94/12285 A2/A3	06-09-1994	Coffee	
	B2	WO 94/14543 A2/A3	07-07-1994	Coffee	
	B3	WO 95/26234 A1	10-05-1995	Coffee	
	B4	WO 95/26235 A1	10-05-1995	Coffee	
	B5	WO 95/32807 A1	12-07-1995	Coffee	
	B6	WO 99/58555 A2/A3	11-18-1999	Hendler et al.	
	B7 *	WO 00/48572 A1	08-24-2000	Morimoto et al.	
	B8	WO 00/54588 A1	09-21-2000	Krusz	
<i>V</i>	B9	WO 02/13810 A1	02-21-2002	Hendler	

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		

Examiner Signature	<i>D. Lamther</i>	Date Considered	<i>5/22/06</i>
--------------------	-------------------	-----------------	----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Substitute for form 1449A/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 4 Attorney Docket Number 34544/US/2/AMP/SKS (459258-00048)

**Complete if Known**

Application Number	10/766,990
Filing Date	January 28, 2004
First Named Inventor	Gallop, Mark A.
Group Art Unit	1626
Examiner Name	Not Assigned

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	↑ C
DA	C1	Adibi, "The oligopeptide transporter (Pept-1) in Human Intestine: Biology and Function," <i>Gastroenterology</i> 1997, 113, 332-340.	
	C2	Alderman, "A Review of Cellulose Ethers in Hydrophilic Matrices for Oral controlled-Release Dosage Forms," <i>Int. J. Pharm. Tech. &amp; Prod. Mfr.</i> 1984, 5(3) 1-9.	
	C3	Anderson et al., "Alpha-amino acid phenolic ester derivatives: novel water-soluble general anesthetic agents which allosterically modulate GABA(A) receptors," <i>J. Med. Chem.</i> 2001, 44, 3582-3591.	
	C4	Bamba et al., "Release Mechanisms in Gelforming Sustained Release Preparations," <i>Int. J. Pharm.</i> 1979, 2, 307.	
	C5	Banaszczyk et al., "Propofol Phosphate, a Water-Soluble Propofol Prodrug: In Vivo Evaluation," <i>Anesth. Analg.</i> 2002, 95, 1285-1292. <i>Cap</i>	
	C6	Borgeat et al., "Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer," <i>Can. J. Anaesth.</i> 1994, 41, 1117-1119.	
	C7	Borgeat et al., "Propofol improves patient comfort during cisplatin chemotherapy. A pilot study," <i>Oncology</i> 1993, 50, 456-459. <i>Cap</i>	
	C8	Briggs et al., "An adverse reaction to the administration of disopropofol (Diprivan)," <i>Anesthesia</i> 1982, 37, 1099-1101.	
	C9	Brooker et al., "Propofol Maintenance to Reduce Postoperative Emesis in Thyroidectomy Patients: A Group Sequential Comparison with Isoflurane/Nitrous Oxide," <i>Anaesth. Intensive Care</i> 1998, 26, 625-629	
	C10	Brown et al., "Role of Propofol in Refractory Status Epilepticus," <i>Pharmacother.</i> 1998, 32, 1053-1059.	
	C11	De la Cruz et al., "The Effect of Propofol on Oxidative Stress in Platelets from Surgical Patients," <i>Anesth. Analg.</i> 1999, 89, 1050-1055	
	C12	During et al., "Controlled release of dopamine from a polymeric brain implant: in vivo characterization," 1989, <i>Ann. Neurol.</i> 25:351.	
	C13	Gan et al., "Determination of Plasma Concentrations of Propofol Associated with 50% Reduction in Postoperative Nausea," <i>Anesthesiology</i> , 1997, 87, 779-784.	
	C14	Hasan et al., "Comparison of the Effects of the Propofol and Thiopental on the Pattern of Maximal Electroschok Seizures in a Rat," <i>Pharmacol. Toxicol.</i> 1994, 74, 50-53. <i>Cap</i>	
	C15	Holtkamp et al., "Propofol in subanesthetic doses terminates status epilepticus in a rodent model," <i>Ann. Neurol.</i> 2001, 49, 260-263.	
	C16	Howard et al., "Intercerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits," 1989, <i>J. Neurosurg.</i> 71:105-112.	
	C17	Krusz et al., "Intravenous Propofol: Unique Effectiveness in Treating Intractable Migraine," <i>Headache</i> 2000, 40, 224-230. <i>Cap</i>	
↓	C18	Kuisma et al., Propofol in prehospital treatment of convulsive status epilepticus. <i>Epilepsia</i> 1995, 36, 1241-1243.	

Examiner Signature	D. Lambkin	Date Considered	5/22/06
--------------------	------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known	
Application Number	10/766,990
Filing Date	January 28, 2004
First Named Inventor	Gallop, Mark A.
Group Art Unit	1626
Examiner Name	Not Assigned

Sheet 3 of 4 Attorney Docket Number 34544/US/2/AMP/SKS (459258-00048)

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>4</sup>
DL	C19	Langer <i>et al.</i> , "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review," <i>J Macromol. Sci. Rev. Macromol Chem.</i> 1983, 23:61. ✓ CAP	
	C20	Langley <i>et al.</i> , "Propofol. A review of its pharmacodynamic and pharmacokinetic properties and use as an intravenous anaesthetic," <i>Drugs</i> 1988, 35, 334-372. ✓ CAP	
	C21	Leibach <i>et al.</i> , "Peptide transporters in the intestine and the kidney," <i>Ann. Rev. Nutr.</i> 1996, 16, 99-119.	
	C22	Levy <i>et al.</i> , "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate," <i>Science</i> 1985 228: 190-192.	
	C23	Murphy <i>et al.</i> , "The Antioxidant Potential of Propofol (2,6-Diisopropylphenol)," <i>Br. J. Anaesth.</i> 1992, 68, 613-618.	
	C24	Peduto <i>et al.</i> , "Biochemical and Electrophysiologic Evidence That Propofol Enhances GABAergic Transmission in the Rat Brain," <i>Anesthesiology</i> 1991, 75, 1000-1009.	
	C25	Phelps <i>et al.</i> , "Propofol in Chemotherapy-Associated Nausea and Vomiting," <i>Ann. Pharmacother.</i> 1996, 30, 290-292.	
	C26	Picard <i>et al.</i> , "Prevention of Pain on Injection with Propofol: A Quantitative Systematic Review," 2000, 90, 963-969.	
	C27	Pop <i>et al.</i> , "Synthesis and Preliminary Pharmacological Evaluation of Some Chemical Delivery Systems of 2,6-Diisopropylphenol (Propofol)," <i>Med. Chem. Res.</i> 1992, 2, 16-21.	
	C28	Raleigh <i>et al.</i> , "Pharmacokinetics of Isotretinoin (ISO) in Rats Following Oral Dosing or Aerosol Inhalation," <i>British J. Cancer</i> , 1999, 80, Suppl. 2, 96.	
	C29	Raleigh <i>et al.</i> , "Searching for the Link Between Hypoxia and Poor Prognoses in Human Tumors," <i>Proc. Amer. Assoc. Cancer Research Annual Meeting</i> , 1999, 40, 397..	
	C30	Raoof <i>et al.</i> , "In Vivo Assessment of Intestinal Hepatic, and Pulmonary First Pass Metabolism of Propofol in the Rat," <i>Pharm. Res.</i> 1996, 13, 891-895	
	C31	Sagara <i>et al.</i> , "Propofol Hemisuccinate Protects Neuronal Cells from Oxidative Injury," <i>J. Neurochem.</i> 1999, 73, 2524-2530.	
	C32	Sauder <i>et al.</i> , "A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery," <i>N. Engl. J. Med.</i> , 1989, 321: 574.	
	C33	Sefton, "Implantable Pumps," <i>CRC Crit Rev Biomed. Eng.</i> 1987, 14:201.	
	C34	Simonian <i>et al.</i> , "Oxidative Stress in Neurodegenerative Diseases," <i>Pharmacol. Toxicol.</i> 1996, 36, 83-106.	
	C35	Sutherland <i>et al.</i> , "Propofol and Seizures," <i>Anaesth. Intensive Care</i> 1994, 22, 733-737.	
✓	C36	Tomioka <i>et al.</i> , "Propofol is Effective in Chemotherapy-Induced Nausea and Vomiting: A Case Report with Quantitative Analysis," <i>Anesth. Analg.</i> 1999, 89, 798-799.	

Examiner Signature	D. Garber	Date Considered	5/22/06
--------------------	-----------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

4

**Complete if Known**

Application Number	10/766,990
Filing Date	January 28, 2004
First Named Inventor	Gallop, Mark A.
Group Art Unit	1626
Examiner Name	Not Assigned

Attorney Docket Number 34544/US/2/AMP/SKS (459258-00048)

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	† <sup>2</sup>
Ma	C37	Tramer <i>et al.</i> , "Propofol Anaesthesia and Postoperative Nausea and Vomiting Quantitative and Systemic Review of Randomized Controlled Studies," <i>Br. J. Anaesth.</i> 1997, 78, 247-255.	
	C38	Trapani <i>et al.</i> , "Propofol Analogues. Synthesis, Relationships Between Structure and Affinity for GABA <sub>A</sub> Receptors," <i>J. Med. Chem.</i> 1998, 41, 1846-1854.	
	C39	Trapani <i>et al.</i> , "Water-Soluble Salts of Aminoacid Esters of the Anesthetic Agent Propofol," <i>Int. J. Pharm.</i> 1998, 175, 195-204.	
	C40	Verma <i>et al.</i> , "Osmotically Controlled Oral Drug Delivery," <i>Drug Dev. Ind. Pharm.</i> , 2000, 26:695-708.	
	C41	Walder <i>et al.</i> , "Seizure-like phenomena and propofol," <i>Neurology</i> 2002, 58, 1327-1332	
	C42	Wang <i>et al.</i> , "Propofol reduces infarct size and striatal dopamine accumulation following transient middle cerebral artery occlusion: a microdialysis study," <i>Eur. J. Pharmacol.</i> 2002, 452, 303-308	
✓	C43	Young <i>et al.</i> , "Propofol neuroprotection in a rat model of ischaemia reperfusion injury," <i>Eur. J. Anaesthesiol.</i> 1997, 14, 320-326. <i>FCP</i>	

Examiner Signature

D. Lambkin

Date Considered

3/22/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.<sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.